IPSC CENTURY THERAPEUTICS INC

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:

  • Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
    • Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
  • Fireside Chat: 4:30 PM ET
    • Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer

A live webcast of the fireside chat can be accessed on the “Events & Presentations” page in the “Investors” section of the Company’s website at . A replay of the webcast will be available for 90 days following the event.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .

For More Information:

Investor Relations & Media Contacts

Century Therapeutics

Katja Buhrer

SVP, Head of Corporate Affairs and Strategy

 

917-969-3438

Argot Partners

Noor Pahlavi

 

212-600-1902



EN
26/11/2024

Underlying

IPSCCENTURY THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTURY THERAPEUTICS INC

 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT...

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will ...

April 28, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prior...

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical c...

April 15, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Reports Full Year 2024 Financial Results and Prov...

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a...

March 19, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial ...

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and enhance clinical experience with CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous sy...

January 21, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Present at the Piper Sandler 36th Annual Healt...

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune Disease Cell Therapy Panel: 3:00 PM ET Presenter: Chad Cowan, Ph.D., Chief Scientific Officer Firesid...

November 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch